©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2017; 9(9): 341-353
Published online Sep 15, 2017. doi: 10.4251/wjgo.v9.i9.341
Published online Sep 15, 2017. doi: 10.4251/wjgo.v9.i9.341
Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective
Brendan M Finnerty, Katherine D Gray, Maureen D Moore, Rasa Zarnegar, Thomas J Fahey III, Department of Surgery, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, United States
Author contributions: Finnerty BM, Gray KD and Moore MD analyzed the data and interpreted data and wrote the manuscript; Zarnegar R and Fahey III TJ made critical revisions to data analysis and interpretation and gave final approval of the version of the article to be published.
Conflict-of-interest statement: There are no conflicts of interest to report.
Correspondence to: Brendan M Finnerty, MD, Department of Surgery, New York Presbyterian Hospital, Weill Cornell Medicine, York Ave, Suite A1027, New York, NY 10065, United States. bmf9002@nyp.org
Telephone: +1-212-7465187 Fax: +1-212-7469948
Received: February 25, 2017
Peer-review started: February 27, 2017
First decision: June 12, 2017
Revised: June 27, 2017
Accepted: August 3, 2017
Article in press: August 4, 2017
Published online: September 15, 2017
Processing time: 197 Days and 23.9 Hours
Peer-review started: February 27, 2017
First decision: June 12, 2017
Revised: June 27, 2017
Accepted: August 3, 2017
Article in press: August 4, 2017
Published online: September 15, 2017
Processing time: 197 Days and 23.9 Hours
Core Tip
Core tip: Herein, we describe a review of the literature addressing known epigenetic changes which are thought to lead to the development of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Through a variety of scientific works, methylation patterns, chromatin remodeling alterations, and microRNA and long non-coding RNA differential expression profiles have been identified and in many cases correlated with GEP-NET malignancy and clinical outcomes. This overview shows the strong foundation which exists and underlines the importance of future work to evaluate the clinical efficacy of epigenetic modifications as prognostic biomarkers, as well as potential therapeutic targets.